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Background
Mometasone furoate/formoterol (MF/F) combination
therapy is a new treatment for persistent asthma. We
report findings from a non-inferiority study that com-
pared effects of MF/F and fluticasone propionate/salme-
terol (FP/S) combination therapies on pulmonary
function and onset of action in subjects with persistent
asthma.
Materials and methods
This randomized, active-controlled, multicenter, non-
inferiority trial enrolled subjects (≥12 yrs) previously
treated with medium-dose inhaled corticosteroid alone
or combined with a long-acting b2-agonist. Following a
2-4 wk run-in treatment period with MF administered
via metered-dose inhaler (MDI) 200 μg twice daily
(BID), eligible subjects were randomized to MF/F-MDI
200/10 μg BID or FP/S administered via dry-powder
inhaler (DPI) 250/50 μg BID for 12 wks. The primary
endpoint was change from baseline in area under the
curve in forced expiratory volume in 1 s 0-12 h post-
dose (FEV1AUC0-12 h). Key secondary endpoints
included onset of action, defined as change from base-
line in FEV1 at 5 min postdose on Day 1.
Results
722 subjects were randomized to MF/F-MDI (n = 371)
or FP/S-DPI (n = 351). MF/F-MDI was found to be
non-inferior to FP/S-DPI for mean FEV1AUC0-12 h at
endpoint (3.43 vs 3.24 Lxh, respectively; 95% CI, -0.40,
0.76). MF/F-MDI’s onset of action was rapid and signifi-
cantly faster than observed for FP/S-DPI (Figure 1), with
a 200 mL mean increase from baseline in FEV1 at 5 min
postdose (first scheduled measurement) on Day 1 for
MF/F-MDI vs 90 mL for FP/S-DPI (P < 0.001).
Conclusions
This non-inferiority trial demonstrated that MDI-admi-
nistered MF/F 200/10 μg BID was non-inferior to DPI-
administered FP/S 250/50 μg BID in FEV1AUC0-12 h. MF/
F-MDI was superior to FP/S-DPI in onset of action.
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Figure 1 Onset of action for MF/F-MDI vs FP/S-DPI
combination therapies.
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